| abstract |
A camptothecin analog for use in treatment of cancer, said analog having the following structural formula: (see above formula) wherein R2 is methyl; R3 is methyl; and R1 is selected from the group consisting of: Vinyl, Chloromethyl, Iodomethyl, Acetomethyl, Hydroxymethyl, Thioacetoxymethyl, Hydroxypropyl, 3-benzenesulfonylpropyl, 3-imidazol-1-yl-propyl, 3-[1,2,4]triazol-1-yl-propyl' 3-dimethylaminopropyl, 3-(2-oxo-2H-pyridin-1-yl)-propyl, the phosphoric acid derivative (-(CH2)3-P(O)(OCH3)2), Propyl trifluoroacetamide, 3-phenylurea, 3,3-diethylurea, 3,3-dimethylurea, [1,2,4]triazol-1-ylmethyl, 2-oxo-2H-pyridin-1-ylmethyl, pyrrolidin-1-ylmethyl, 1-methyl-1H-imidazol-2-ylsulfanylmethyl, 2-[4,5-dihydro -thiazol-2-ylsulfanylmethyl, 2-hydroxy-ethylsulfanylmethyl, 4-chlorobenzenesulfonamidomethyl, 3-phenylurea, 3,3-diethylurea, 3,3-dimethylurea, and hydroxy, and pharmaceutically-acceptable salts thereof. |